Dianthus Therapeutics (DNTH) Gains from Investment Securities (2017 - 2025)
Historic Gains from Investment Securities for Dianthus Therapeutics (DNTH) over the last 6 years, with Q3 2025 value amounting to $6.4 million.
- Dianthus Therapeutics' Gains from Investment Securities rose 4114.11% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year increase of 4114.11%. This contributed to the annual value of $4.5 million for FY2024, which is 15720.3% up from last year.
- Latest data reveals that Dianthus Therapeutics reported Gains from Investment Securities of $6.4 million as of Q3 2025, which was up 4114.11% from $6.2 million recorded in Q2 2025.
- Over the past 5 years, Dianthus Therapeutics' Gains from Investment Securities peaked at $6.4 million during Q3 2025, and registered a low of -$3.3 million during Q2 2023.
- In the last 3 years, Dianthus Therapeutics' Gains from Investment Securities had a median value of $3.1 million in 2023 and averaged $2.7 million.
- Examining YoY changes over the last 5 years, Dianthus Therapeutics' Gains from Investment Securities showed a top increase of 117481.03% in 2025 and a maximum decrease of 4100.82% in 2025.
- Dianthus Therapeutics' Gains from Investment Securities (Quarter) stood at -$46000.0 in 2023, then skyrocketed by 1154.35% to $485000.0 in 2024, then skyrocketed by 1209.55% to $6.4 million in 2025.
- Its last three reported values are $6.4 million in Q3 2025, $6.2 million for Q2 2025, and $5.9 million during Q1 2025.